Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments

Author： Locati Laura D. Licitra Lisa Agate Laura Ou Sai-Hong I. Boucher Andree Jarzab Barbara Qin Shukui Kane Madeleine A. Wirth Lori J. Chen Connie Kim Sinil Ingrosso Antonella Pithavala Yazdi K. Bycott Paul Cohen Ezra E. W.

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|17|2694-2703

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.17, 2014-09, pp. : 2694-2703

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

By Adolfsson J.

PharmacoEconomics, Vol. 21, Iss. 4, 2003-01 ,pp. : 241-247

Adis International

Access to resources Recommend Favorite

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

By Spano Jean-Philippe

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1531-1539

Springer Publishing Company

Access to resources Recommend Favorite

Axitinib for the treatment of advanced non-small-cell lung cancer

By King Judy W

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 765-773

Informa Healthcare

Access to resources Recommend Favorite

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women

By Land Stephanie

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 415-416

Adis International

Access to resources Recommend Favorite

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women

By Milne Richard J. Heaton-Brown Kathy H.

PharmacoEconomics, Vol. 24, Iss. 3, 2006-01 ,pp. : 281-292

Adis International

Access to resources Recommend Favorite